Prominent ophthalmologist will guide Turn Bio’s search for therapies to cure eye diseases

MOUNTAIN VIEW, Calif., Aug. 22, 2022 /PRNewswire/ — Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that Albert Wu, MD, PhD, will oversee its development of ophthalmic therapeutic products as an advisor to the company. A board-certified ophthalmologist and fellowship-trained specialist in oculoplastic and orbital surgery, […]
Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ — Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research. Sebastiano led development of the unique mRNA-based ERA™ (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored […]